The European Commission has approved Byetta® (exenatide) for treatment of Type 2 diabetes. This drug is a new class of anti-diabetic drug known as incretin mimetics. The European Commission has permitted marketing and sale of Byetta (exenatide). To improve the blood sugar control in patients with type 2 diabetes the European Union has authorized exenatide as adjunctive therapy. This is for patients who have not accomplished adequate glycaemic control on maximally tolerated doses of two common oral medications viz. metformin and/or a sulfonylurea. Exenatide is the first in its class of medicines.
Patients have long-term blood sugar control with the help of exenatide. This was revealed in the clinical trials conducted by the company. The drug lowers both fasting and postprandial glucose levels (peak levels after meals). To gauge blood glucose management health care providers often use of haemoglobin A1c. The haemoglobin A1c measures a person’s average glucose level over a period of three months. Most patients also benefit from the resultant weight loss when this drug is used.
Studies undertaken compared exenatide to insulin, it was revealed that exenatide controls blood sugar as effectively as insulin, often used in patients who do not respond to oral agents. Patients who were treated with exenatide lost weight whereas treatment with insulin was linked to weight gain. By the use of one or more oral medications if the patients are unable to control their blood sugar then they can have exenatide as an option.
There is a rapid increase in the prevalence of diabetes and as such the need for innovative new treatments is grave. Exenatide is one of the new treatment options for the management of type 2 diabetes which has the approval of health care professionals and patients in all European countries. Exenatide is formulated for self-administration as a fixed dose; subcutaneous injection is given preceding morning and evening meals, or two main meals of the day. Mild to moderate nausea that was dose dependent was reported in clinical trials as a most common adverse event. In most patients the occurrence and the sternness of nausea diminished over time with continued therapy. The self-regulation action of exenatide is consistent and it motivates the discharge of insulin as and when needed. This reduces the likelihood of hypoglycaemia (low blood sugar) significantly.
In our battle with diabetes, incretin mimetics represent a new class of medicines. Incretins are naturally occurring human hormones. The work of an incretin mimetic is to mimic the anti-diabetic or glucose-lowering action of incretins. These actions include encouraging the body’s capacity to produce insulin in reaction to raising levels of blood sugar. This restrains the release of a hormone called glucagon following meals. This also slows the rate at which nutrients are absorbed into the blood stream. The first FDA- approved incretin mimetic is exenatide
Lilly is the industry leader in pioneering therapies since 1923. The life of people with diabetes has been considerably improved by dedicated professionals from Lilly.
Lilly continues its research on innovative medications in order to address the needs of patients. Lilly has a long- standing reputation of diabetes care. Thanks to Lilly diabetics are living healthier, fuller and longer lives.
An Excellent Healthy Drink for Diabetics!
Did you know that flavored carbonated water has no calories, sugar, body, sweetener, color or preservatives?
The taste is fantastic, extremely refreshing and gives diabetics a great drink without any carbohydrates. A large
and affordable assortment of flavored carbonated water concentrate is available for free delivery world wide from